Nav: Home

UA part of international alliance to address African antivenom crisis

March 15, 2017

Venomous snakebites kill an estimated 150,000 people around the world each year -- amid severe shortages of fair-priced antivenom and health providers trained to use the lifesaving treatment.

Now, an international alliance with experts from the United States, Mexico and Africa has come together to address the issue with a project to improve access to quality antivenoms and to save lives in regions with high snakebite incidence.
  • The African Society of Venimology (Societe Africaine de Venimologie, SAV-ASV)
  • The Institute of Biotechnology of the National Autonomous University of Mexico (Instituto de Biotecnologia, IBt/UNAM)
  • The VIPER Institute, University of Arizona


The alliance partners are developing a series of educational videos, with English, French and Spanish subtitles, to educate African health professionals about the appropriate use of antivenom and the best practices for the care of snakebite patients. A preview module is available online in French, English and Spanish.

French, English and Spanish.

The alliance also is working with government, industry and other collaborators to develop and introduce high-quality, fair-priced antivenom treatments to sub-Saharan Africa.

"In short, the world lacks sufficient antivenom for those who need it most; most doctors lack training to use it; and the per-dose cost to provide antivenom in low quantities is extremely high," said Leslie Boyer, MD, director of the UA Venom Immunochemistry, Pharmacology and Emergency Response (VIPER) Institute. Correcting the problem will require simultaneous effort by physicians, patients, ministries of health and drug companies, she said.

Ensuring sub-Saharan Africa has sufficient fair-priced antivenom also will benefit the United States and other Western nations. "The United States needs a legal and affordable way to obtain successful world antivenoms for the rare cases where our citizens are bitten by snakes from other places," Dr. Boyer explained.

Dr. Achille Massougbodji, president of the African Society of Venimology, said, "Roughly 5 million people are bitten by venomous snakes each year worldwide, of whom about 150,000 die. The problem is especially severe in sub-Saharan Africa, where we have had shortages of good antivenom for many years. Experts in the African Society of Venimology are working to reduce the number of people who die or are disabled, but we need safe, effective antivenom."

Dr. Alejandro Alagon, professor at IBt/UNAM, said, "Making good antivenom for a region - such as sub-Saharan Africa - depends on excellent collaboration and communication. We need to know exactly which snake venoms to use, how big a dose is required and what the pharmacy storage conditions are like. The biotechnology alliance needs to have the best possible information from experts in Africa."

Antivenoms developed by Alagon and colleagues within the alliance are used to treat 1,000 patients per day around the world.

"Modern technology makes it possible to manufacture sufficient quantities of high-quality, heat-stable antivenom, but market conditions in Africa can be very challenging. Certification of good products by trusted authorities, and large-scale purchases by governments, have helped to bring quality up and costs down," said Juan Lopez de Silanes, president of Inosan Biopharma, which manufactures antivenom for use in Africa, the Middle East, Europe and North America, including a coral snake antivenom currently in clinical trials in the United States.

"Even a certified, high-quality antivenom won't save lives unless it is properly used," Dr. Boyer said. "Effective education of doctors, nurses, public health professionals and the public has to happen in advance - because an incorrectly treated snakebite can kill in a matter of hours. And making it possible for doctors to treat a cobra or mamba bite effectively is doubly difficult in North America, where the smaller number of cases means that medical teams are less-prepared than in Africa," she added.

To help meet these challenges, the international snakebite treatment alliance is collaborating with Ray Morgan, producer of the acclaimed documentary, "The Venom Interviews," which details the activities of U.S. herpetologists involved in venom production and research. Together, the group is producing the series of short training videos, which will become available over the coming year.

"Today's video technology allows international experts to share information fast, anywhere in the world. Doctors, scientists, government representatives and businesses in Africa, Mexico and the United States can work together like never before, and they can post their knowledge online, where colleagues and students can find it at a minute's notice, whether they speak English, French or Spanish," Morgan said.

Noted physician and epidemiologist Dr. Jean-Philippe Chippaux, founder of the SAV-ASV, said, "By working together and applying modern communications and manufacturing technology, we can overcome the vicious circle of antivenom shortage that has plagued sub-Saharan Africa for decades. One of the greatest needs is for the training of health personnel at all levels. The African Society of Venimology is enthusiastic to share our knowledge with the Institute of Biotechnology at UNAM and the VIPER Institute at the UA and to create a set of training modules for the benefit of medical professionals in Africa and around the world."
-end-
Photos available to view and download at http://opa.ahsc.arizona.edu/african-antivenom-crisis-release-photos
  • Snake
  • Patient
  • Collaboration "in action"
  • Individuals quoted in release


Find us:
  • UA VIPER Institute, viper.arizona.edu
  • Institute of Biotechnology, morelos.unam.mx
  • African Society of Venimology (Societe Africaine de Venimologie, SAV-ASV), on FaceBook: facebook.com/groups/venimologie; on Twitter, @Venimologie


For additional information, please contact:

About the University of Arizona Health Sciences

The University of Arizona Health Sciences is the statewide leader in biomedical research and health professions training. The UA Health Sciences includes the UA Colleges of Medicine (Phoenix and Tucson), Nursing, Pharmacy and Mel and Enid Zuckerman College of Public Health, with main campus locations in Tucson and the growing Phoenix Biomedical Campus in downtown Phoenix. From these vantage points, the UA Health Sciences reaches across the state of Arizona and the greater Southwest to provide cutting-edge health education, research, patient care and community outreach services. A major economic engine, the UA Health Sciences employs almost 5,000 people, has nearly 1,000 faculty members and garners more than $126 million in research grants and contracts annually. For more information: http://uahs.arizona.edu (Follow us: Facebook | Twitter | YouTube | LinkedIn)

University of Arizona Health Sciences

Related Biotechnology Articles:

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.
Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.
China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.
Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.
Novel 'repair system' discovered in algae may yield new tools for biotechnology
The algae C. reinhardtii uses a novel system for releasing an interrupting sequence from a protein -- a technique that may be useful for protein purification.
ESIB -- European Summit of Industrial Biotechnology 2016
'Design' will be the guiding thread of the 2½ days ESIB 2016 which will cover trends in biotech science and industry, cascade design and metabolic engineering, designing nature (e.g. proteins for competitive bioprocesses), in-silico approaches in modern industrial biotechnology, networking opportunities and much more.
Werner Siemens Foundation fosters synthetic biotechnology
With its donation of 11.5 million euro, the Werner Siemens Foundation has facilitated the launch of the teaching and research domain Synthetic Biotechnology at the Technical University of Munich (TUM).
Sanyal Biotechnology LLC announces strategic partnership with OWL Metabolomics, S.L.
Sanyal Biotechnology LLC and One Way Liver S.L. (OWL Metabolomics) have initiated a strategic partnership to provide increased value and additional R&D services to basic research and the pharmaceutical industry, announced at the International Liver Congress in Barcelona, Spain.
ASU researcher improves crop performance with new biotechnology
Researchers with Arizona State University's School of Life Sciences have discovered a way to enhance a plant's tolerance to stress, which in turn improves how it uses water and nutrients from the soil.
New biotechnology to inhibit microRNA activity and novel applications
Today at the 45th Annual Meeting & Exhibition of the American Association for Dental Research, researcher Brad Amendt, University of Iowa, Iowa City, USA, will present a study titled 'New Biotechnology to Inhibit MicroRNA Activity and Novel Applications for Craniofacial and Dental Research.'

Related Biotechnology Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...